Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 40 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 548 pembrolizumab 384 Radiotherapy 363 Bevacizumab 360 Carboplatin 351 Rituximab 315 Cisplatin 300 Gemcitabine 297 Paclitaxel 288 Dexamethasone 272 Docetaxel 271 fludarabine phosphate 241 Doxorubicin 231 Nivolumab 220 Etoposide 209 Cytarabine 203 Lenalidomide 201 fludarabine 191 Oxaliplatin 191 Fluorouracil 190 Melphalan 189 Filgrastim 188 Capecitabine 175 Calcium Dobesilate 172 Radiosurgery 167 Erlotinib Hydrochloride 167 Methotrexate 163 Bortezomib 162 Granulocyte Colony-Stimulating Factor 154 Whole-Body Irradiation 144

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Has results × tislelizumab × Clear all

NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

16 enrolled 14 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡